Introduction
============

Brain tumors represent the leading cause of childhood cancer mortality, of which medulloblastoma (MB) is the most common malignant pediatric brain tumor. MB most often arises in the cerebellum of infants and young children, and was originally described as a primitive neuroectodermal tumor.^[@bib1],\ [@bib2]^ Although tremendous improvements in therapy regimens using a combination of surgical resection, craniospinal irradiation and chemotherapy with vincristine, cisplatin and cyclophosphamide have yielded 5-year overall survival rates of 70--80%, survivors are left with substantial neurocognitive impairments and treatment-related morbidity.^[@bib3],\ [@bib4]^

MB has been classified into four principal subgroups using integrative genomic platforms.^[@bib1],\ [@bib2]^ Groups 1 and 2, referred to as WNT and sonic hedgehog (SHH), derive from dysregulation of these key developmental signaling pathways and Groups 3 and 4 are associated with the strong upregulation of c-MYC and N-MYC, respectively.^[@bib2],\ [@bib5],\ [@bib6]^ This subgroup stratification has generated four genetically distinct tumor identities, each with a characteristic clinical presentation and prognosis.^[@bib7]^ Group 3 tumors have shown the worst prognosis of all, emphasizing the need for the development of specialized therapeutics in this subgroup.^[@bib8]^ Recent reports suggest the presence of somatic copy-number aberrations and single-nucleotide variants that may present subgroup-specific therapeutic targets^[@bib9],\ [@bib10]^ but to date, druggable targets for Group 3 MB have not been identified.

As in many other solid tumors^[@bib11]^ and hematopoietic cancers,^[@bib12]^ MB is characterized by the presence of cancer stem cells (CSCs) or MB stem cells (MBSCs) that possess the ability to sustain tumor growth. These cells were first isolated and characterized in 2004.^[@bib13]^ CD133 (Prom1), a pentaspan membrane glycoprotein, is a surface marker for MBSCs, although its functional role and signaling mechanisms are not well understood.^[@bib13],\ [@bib14]^ Although some studies debate the role of CD133 in initiating tumors,^[@bib15]^ CD133-positive cells continue to retain a higher self-renewal capacity and multipotency.^[@bib16]^

The signal transducers and activators of transcription (STAT) family of transcription factors are present in the cytoplasm as inactive monomeric/dimeric forms and upon phosphorylation at key tyrosine residues (Tyr705), STATs translocate to the nucleus. This movement from cytoplasm to nucleus is due to reciprocal SH2 domain--pTyr binding interactions between two STAT molecules, leading to the formation of activated homodimers.^[@bib17]^ Upon nuclear translocation, these activated homodimers promote expression of genes that regulate cell growth, cell survival and cell cycle regulation. In cancer cells, continual activation of STATs, more specifically STAT3, leads to modulation of several cell cycle regulators to promote a state of tumorigenesis.

Numerous cancers such as leukemia, lymphoma,^[@bib18]^ breast,^[@bib19]^ ovarian^[@bib19]^ and prostate^[@bib20]^ cancer display aberrant activation of STAT3 signaling. In brain tumors, especially glioblastoma, recent signaling network profiling identified STAT3 as one of the key transcription factors modulating poor outcome in the mesenchymal subtype.^[@bib21]^ In patient-derived glioblastoma brain tumor-initiating cells, STAT3 signaling is prognostically significant and can be targeted in orthotopic mouse models.^[@bib22]^

Here, we describe a method for treatment of Group 3 MBSCs by targeting STAT3 transcription factor signaling. We sorted human Group 3 MBSCs based on CD133 expression and showed upregulation of p-STAT3 and c-MYC in these cells compared with CD133-negative subpopulations. Thereafter using structure-based drug design, we developed novel STAT3 inhibitors that have the potential to cross the blood-brain-barrier, to treat MB *in vivo*. Although CD133 has been used primarily as a marker to identify CSCs in multiple human cancers including brain tumors, its functional role remains obscure and cannot be currently targeted using small molecules or inhibitors. Similarly, c-MYC is difficult to target due to our poor understanding of binding ligands and inability to specify context-dependent MYC-associated transcriptional gene expression across different cancers.^[@bib23]^ Our study presents a preclinical model applying STAT3 inhibitors to selectively target CD133^+^ MBSCs in Group 3 MB.

Results
=======

CD133 expression is upregulated in Group 3 MB cells
---------------------------------------------------

CD133 is a marker used to enrich for human MBSCs,^[@bib6],\ [@bib13],\ [@bib14],\ [@bib24]^ but its role and expression within subgroups remains unclear. To evaluate CD133 protein expression in MBSCs, we propagated in neural stem cell (NSC) media the MB Group 3 lines Med8A, D425, D458, CHLA-01R-MED, and measured CD133 expression by flow cytometery ([Figure 1a](#fig1){ref-type="fig"}). It is noteworthy that D425 was derived from a primary cerebellar MB in a 6-year-old boy, whereas D458 was established from cerebrospinal metastasis after treatment failure from the same patient; thus D425 and D458 represent a matched primary and recurrent pair.^[@bib25]^ Interestingly, CD133 expression was significantly higher in recurrent MB lines (D458, CHLA-01R-MED) compared with primary (D425) lines. Phase-contrast pictures of MB cell lines are shown in [Figure 1b](#fig1){ref-type="fig"}.

When we probed multiple published MB transcriptional databases (Toronto,^[@bib5]^ Boston,^[@bib26]^ Amsterdam^[@bib27]^ and Memphis^[@bib28]^) for CD133 we found its expression was strongly associated with Group 3 MB ([Figure 1c](#fig1){ref-type="fig"}). Data mined from the Boston database showed lower survival in CD133^high^ tumors (*P*=0.01, hazard ratio=2.4) compared with CD133^low^ tumors ([Figure 1d](#fig1){ref-type="fig"}). To provide a functional context for the clinical utility of CD133 expression in Group 3 MB, we compared the proliferative potential between sorted CD133-positive and CD133-negative populations. When compared with CD133-negative cells, CD133-positive cells had significantly higher proliferation capacity in both primary and matched recurrent cells lines (D425 and D458, respectively, [Figures 1e and f](#fig1){ref-type="fig"}).

To further validate the functional role of CD133 in tumor formation, we xenografted mice intracranially with sorted CD133-positive or CD133-negative Group 3 MB cells. We found that CD133-positive cells formed very large tumors, whereas tumors obtained by xenograting CD133-negative cells were much smaller ([Figure 1g](#fig1){ref-type="fig"}). Our data suggests that CD133 expression characterizes and may contribute to poor outcome in Group 3 MB through perpetuation of stem cell populations that drive tumorigenesis.

Activated STAT3 is enriched in CD133-high Group 3 MB
----------------------------------------------------

Activated STAT3 signaling has been described in other CSC populations, including CD133-positive human colon cancer cell lines^[@bib29]^ and CD133^high^ hepatocellular carcinoma cell lines.^[@bib30]^ As high CD133 expression is a poor prognostic marker in many cancers^[@bib31]^ and we show that it correlates with poor patient outcome in Group 3 MB ([Figure 1d](#fig1){ref-type="fig"}), we hypothesized that hyperactive signaling pathways in CD133-positive cells could be ideal therapeutic targets. In order to determine transcript levels of STAT3 among MB subgroups, we probed existing MB genomic platforms for its expression levels in different subgroups, as described previously for CD133. STAT3 expression levels were enriched in poor outcome non-Shh/Wnt subgroups, namely Group 3 and Group 4 MB ([Figure 2a](#fig2){ref-type="fig"}). We then determined protein levels of CD133, STAT3 and p-STAT3 in Group 3 MB cells using Western blot, and again validated that recurrent lines, D458 and CHLA-01R-MED have comparatively higher expression of CD133 than D425 line ([Figure 2b](#fig2){ref-type="fig"}). Although STAT3 expression is not significantly altered, activated STAT3 (p-STAT3) correlates with CD133 expression, and is especially elevated in recurrent Group 3 MB ([Figure 2b](#fig2){ref-type="fig"}). To further probe the relationship between CD133 and activated STAT3 signaling, we ectopically overexpressed CD133 in the CD133^low^ Med8A Group 3 line. We validated overexpression of CD133 by RTPCR ([Figure 2c](#fig2){ref-type="fig"}) and Flow analysis ([Figure 2d](#fig2){ref-type="fig"}). Upon overexpression of CD133, MED8a cells showed a significant increase in p-STAT3 ([Figure 2e](#fig2){ref-type="fig"}). Med8A cells overexpressing CD133 also showed increased proliferation capacity ([Figure 2f](#fig2){ref-type="fig"}). Our data demonstrates that STAT3 signaling is activated in CD133+ Group 3 recurrent MB cells, and CD133 overexpression activates STAT3 to promote cell proliferation and growth of Group 3 MB.

p-STAT3 contributes to tumorigenesis in Group 3 MB
--------------------------------------------------

To investigate the role of STAT3 signaling in MB pathogenesis, we undertook lentiviral short-hairpin RNA-mediated knockdown of STAT3 in Group 3 patient-matched MB cell lines D425 (primary) and D458 (recurrent). Out of two vectors, shSTAT3-1 showed efficient knockdown in both cell lines D425 ([Figure 3a](#fig3){ref-type="fig"}) and D458 ([Figure 3b](#fig3){ref-type="fig"}) with prominent reduction in activated p-STAT3 levels. This knockdown correlated with reduction in proliferation capacity in both primary and recurrent MB ([Figures 3c and d](#fig3){ref-type="fig"}). To further elucidate the role of STAT3 in tumor initiation/maintenance, we performed intracranial injections of STAT3-knockdown MB cells into NOD-SCID mice and found a significant reduction in tumor size when compared with control (shControl-transduced) tumors ([Figures 3e--g](#fig3){ref-type="fig"}). Moreover, mice xenografted with shSTAT3-transduced cells treated survived longer than control mice ([Figures 3h and i](#fig3){ref-type="fig"}). These data demonstrate the prominent role of STAT3 in regulating proliferation and tumorigenesis of Group 3 MBSCs.

Interplay between CD133, STAT3 and c-MYC may drive Group 3 MB
-------------------------------------------------------------

c-MYC drives a regulatory network in embryonic stem cells that is also active in many cancers and drives poor outcomes.^[@bib32]^ c-MYC is further implicated in regulating Group 3 murine MBs that resemble their human counterpart.^[@bib6]^ CD133 and c-MYC have clearly been associated with relapse and poor prognosis in MB patients.^[@bib6]^ To explore how CD133, c-MYC and STAT3 may collectively regulate MBSCs,^[@bib30],\ [@bib33],\ [@bib34]^ we first probed MB transcriptome data to validate that c-MYC is highly enriched in Group 3 MB tumors ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Although Group 3 MB lines used (D425, D458, Med8A and CHLA-01R-MED) showed varied mRNA expression levels of c-MYC ([Figure 4a](#fig4){ref-type="fig"}), protein levels of c-MYC were higher in Group 3 recurrent lines D458 and CHLA-01R-MED ([Figure 4b](#fig4){ref-type="fig"}).

c-MYC is a known downstream target of STAT3 signaling in ovarian cancer and in glioblastoma stem cells, where STAT3 inhibitors have also reduced expression of stem cell-associated genes such as CD133. We show that p-STAT3 is upregulated in sorted CD133-positive populations from Group 3 MB lines, which also show enhanced c-MYC levels compared with CD133-negative populations ([Figure 4c](#fig4){ref-type="fig"}). Moreover, as a proof of principle we looked at the levels of STAT3 and c-MYC after knockdown of STAT3 in both D425 and D458 cell lines and found significant downregulation of c-MYC after STAT3 knockdown ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). Expression levels of c-MYC are significantly higher in sorted CD133-positive cells compared with CD133-negative cells in D458 MB ([Figure 4d](#fig4){ref-type="fig"}). Given the high levels of c-MYC in Group 3 MB, we performed proliferation assays using a cell permeable c-MYC inhibitor, 10058-F4,^[@bib35]^ to investigate whether targeting c-MYC could reduce tumor cell growth. Our results ([Figure 4e](#fig4){ref-type="fig"}) showed that Group 3 MB cell proliferation is attenuated by this c-MYC inhibitor, but only with an 50% inhibitory concentration values (IC~50~; concentration at which cell proliferation is inhibited by 50%) in the high micromolar range (D425: 189.148 μ[M]{.smallcaps} and D458: 133.277 μ[M]{.smallcaps}). However, pharmacodynamic studies and screening of other c-Myc inhibitors are necessary to draw conclusions about the utility of c-Myc inhibitors as therapeutics for Group 3 MB. Nevertheless, c-MYC is a highly pleiotropic transcription factor that controls expression of hundreds of genes and may prove challenging to target. This prompted us to seek alternate means to target the CD133/STAT3/c-MYC signaling axis in Group 3 MB.

*Ex vivo* treatment with STAT3 inhibitors reduces MB tumor burden *in vivo*
---------------------------------------------------------------------------

We tested various STAT3 inhibitors from our library ([Supplementary Figures 3 and 4](#sup1){ref-type="supplementary-material"}) and found PG-S3-002 to have selective activity towards CD133-positive MBSCs with IC~50~ in the low micromolar range, in both primary and recurrent MB cells ([Figures 5a and b](#fig5){ref-type="fig"}). A reduction in p-STAT3 protein levels was observed following treatment with PG-S3-002 at IC~80~ ([Figures 5c and d](#fig5){ref-type="fig"}). Intracranial xenograft injections of 1.0 × 10^5^ viable STAT3 inhibitor-treated cells resulted in significantly smaller tumors ([Figures 5e--g](#fig5){ref-type="fig"}) compared with control cells. When we treated normal human NSCs with PG-S3-002, we found an IC~50~ value also in the low micromolar range ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). This data shows that STAT3 inhibitor treatment at doses that would be tolerable in patients can decrease tumor burden of Group 3 MB xenografts, but with equal toxicity towards NSCs; implicating neurotoxicity as a potential side effect.

Systemic treatment with STAT3 inhibitors PG-S3-009 and PG-S3-010 reduces tumor formation *in vivo*
--------------------------------------------------------------------------------------------------

As STAT3 signaling is active in MBSCs, we then investigated the role of STAT3 compounds in reducing tumor formation in our human-mouse xenograft model of Group 3 MB. We chose to xenograft recurrent MB lines that are refractory to conventional chemoradiotherapy, and first tested whether STAT3 inhibitors would target these cells *in vitro*. Both PG-S3-009 and PG-S3-010 compounds showed IC~50~ values in the low micromolar range and selectivity for recurrent MBSCs ([Figure 6a](#fig6){ref-type="fig"}, [Supplementary Figures 7a and b](#sup1){ref-type="supplementary-material"}). These two inhibitors are highly selective for recurrent (D458) MB, when compared with matched primary MB ([Supplementary Figure 6](#sup1){ref-type="supplementary-material"}). Our 2-week treatment protocol comprised PG-S3-009 and PG-S3-010 administration by intraperitoneal injections (20 mg/kg dose, twice a week), following tumor engraftment. Mice were culled and brains harvested at treatment completion for both control (DMSO) and inhibitor-treated mice ([Figure 6b](#fig6){ref-type="fig"}). Mice treated with PG-S3-009 or PG-S3-010 maintained a reduction in tumor burden ([Figures 6c and d](#fig6){ref-type="fig"}), with PG-S3-009 showing the greatest efficacy and potency. These data demonstrates selected STAT3 inhibitors to be efficacious in targeting recurrent, treatment-refractory Group 3 MBSCs.

PG-S3-009 treatment significantly decreases tumor size of recurrent Group 3 MB *in vivo*, but does not increase survival
------------------------------------------------------------------------------------------------------------------------

D458 cells were treated with PG-S3-009 in varying doses *in vitro* and found that cellular levels of STAT3, p-STAT3 and c-MYC gradually decreases with increasing concentration of PG-S3-009 ([Figure 7a](#fig7){ref-type="fig"}). These data implicate the direct targeting of STAT3 by PG-S3-009 and subsequent downregulation of STAT3 leading to the reduction of the downstream target c-MYC in MBSCs ([Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). In order to evaluate the effect of the drug *in vivo*, NODSCID mice were intracranially xenografted with D458 cells and treated intraperitoneal with escalating doses of PG-S3-009 (DMSO, 5, 10 or 20 mg/kg) ([Figure 7b](#fig7){ref-type="fig"}). Cohorts treated at 20 mg/kg with PG-S3-009 showed significant reduction in tumor burden compared with DMSO or lower-dose treated mice ([Figures 7c and d](#fig7){ref-type="fig"}). However, no survival benefit was observed in treated mice compared with DMSO controls ([Figure 7e](#fig7){ref-type="fig"}). Treated mice became anorexic and withdrew from feeding and activity, suggestive of treatment-induced neurotoxicity, although no toxicity was seen in liver, kidneys and lungs (data not shown). These data implicate the direct targeting of STAT3 by PG-S3-009 and subsequent downregulation of STAT3 leading to the reduction of the downstream target c-MYC in MBSCs ([Supplementary Figure 8](#sup1){ref-type="supplementary-material"}).

Discussion
==========

The recent molecular classification of MB into four distinct subgroups implies that different subrgoup-specific therapeutic strategies need to be devised for individualized patient therapy. This therapeutic roadmap may only be realized by elucidating the biological and genetic drivers of tumorigenesis in each subgroup, in order to discover tractable and druggable therapeutic targets. In this study, we link the high expression of CD133 with Group 3 MB and further correlate its expression with c-MYC, via STAT3. High c-Myc expression often reflects a classic Group 3 MB with metastasis at diagnosis, large cell histology and overall poor prognosis.^[@bib2]^ Novel mouse models have been developed using genetics to recapitulate human Group 3 MB that have the potential to be used for preclinical testing.^[@bib6],\ [@bib36]^

Our observation of enrichment of CD133 in Group 3 MB is in accordance with the expression of this cell-surface marker in multiple CSC populations, which are thought to evade current chemoradiotherapy only to seed recurrent disease and drive patient relapse and poor outcome.^[@bib14]^ In light of the fact that Group 3 MB is the most aggressive among all subgroups, our understanding of the functional role of CD133 in Group 3 MB can provide a strategic platform to identify novel signaling inhibitors in CD133-positive cells for the effective management of these tumors. c-MYC expression can be regulated by numerous signaling pathways including the JAK/STAT, rendering STAT3 inhibitors attractive therapeutic options. As the Wnt subtype of MB (Group 1) also demonstrates elevated levels of c-Myc, STAT3 inhibitors could be considered as a therapeutic option for patients with this positive prognostic MB subtype.

Activated STAT3 signaling has been shown to be essential for cell survival and tumorsphere-forming capacity in human colon cancer cell lines sorted for both ALDH (aldehyde dehydrogenase) and CD133 (ALDH^+^/CD133^+^).^[@bib29]^ Previous studies have shown that downregulation and inhibition of STAT3 signaling suppresses proliferation and induces apoptosis in human glioma cells^[@bib37],[@bib38],[@bib39]^ as well as various cancers.^[@bib40],\ [@bib41]^ Xiao et al., have already shown that disruption of STAT3 signaling leads to inhibition of cell growth and apoptosis of medulloblastoma cells.^[@bib42]^ Using bioinformatics and microarray platforms, another study revealed STAT3/p-STAT3 signaling upregulated in CD133-positive MB cells compared with CD133-negative cells.^[@bib43]^ STAT3 has a key role in maintaining both tumor cells and its microenvironment, although little is known about both upstream and downstream regulators of JAK--STAT3 signaling. Despite advances in studying the role of STAT3 as an ideal target for CSC-driven tumors,^[@bib30],\ [@bib33],\ [@bib44]^ challenges have arisen in developing these drugs for clinical use. In general STAT3 inhibitors targeting the SH2 domain have suffered from limited clinical utility due to inclusion of polar groups designed to mimic SH2 domain binding Tyr705 residue that has resulted in metabolic instability and poor cell permeability.^[@bib42],\ [@bib45]^ Non-phosphorylated small molecule inhibitors such as STA-201,^[@bib46]^ BP-1-102,^[@bib47]^ BP-5-87,^[@bib48]^ SH-4-54^[@bib44]^ and LY5^[@bib42]^ have, to a certain extent circumvented this problem.

To enhance *in vivo* efficacy, SH-4-54 was optimized specifically to yield inhibitors with improved bioavailability. PG-S3-009 and PG-S3-010 were two of the most potent anti-cancer compounds to emerge from this program. These inhibitors have shown great promise in treating other treatment-refractory and aggressive cancers such as brain metastases.^[@bib49]^

Previous studies have suggested that c-MYC is a critical regulator of MB cell growth and proliferation.^[@bib32]^ The activation of STAT3 in MB^[@bib50]^ and its translocation to the nucleus permits activation of oncogenes and cell cycle regulatory genes such as *c-MYC*, *cyclin-D1* and *Cox-2*, leading to cancer progression.^[@bib51]^ In another study, DNA microarray analysis in CD133-positive MB cells showed an upregulation of c-MYC.^[@bib52]^ Although both CD133 and c-MYC upregulation have clear implications in Group 3 MB pathogenesis, both are difficult to target owing to insufficient understanding of molecular mechanisms and their role in normal development and cancer. Currently there are no available drugs targeting CD133, and the c-MYC targeting compound 10058-F4^[@bib35]^ has a very high IC~50~ value in MBSCs that may preclude clinical use. There are currently no clinically approved therapies for directly targeting c-MYC, as MYC is a pleiotropic transcription factor that controls expression of hundreds of genes. Moreover, 10058-F4 inhibits c-MYC/Max dimerization,^[@bib35]^ implying multiple off-target cellular activities through modulation of various transcription factors in other tissues and organs. Within the CD133/STAT3/c-MYC signaling axis, the only attractive target for drug development is STAT3. This concept prompted us to search for novel STAT3 inhibitors to treat Group 3 MB with the potential to translate into clinical settings.

In this study, we demonstrate the enrichment of CD133 in Group 3 MBSCs and discover potential signaling mechanisms involving activated STAT3 (p-STAT3) and c-MYC in CD133-positive cells. Treatment with STAT3 dimerization inhibitor PG-S3-002 *ex vivo* significantly reduces tumor burden in mice. Our preclinical trial of another STAT3 inhibitor, PG-S3-009, showed reduced tumor burden in mice, but no significant survival benefit due to presumed neurotoxicity of the compound. However, if neurotoxicity could be mitigated with chemical modifications to the compound, these inhibitors show great promise in effectively treating recurrent MB (D458), an important result as Group 3 recurrence is currently treated with palliation alone. Our study describes the first preclinical evidence that novel STAT3 inhibitors cross the blood-brain-barrier and effectively treat recurrent Group 3 MB.

Materials and methods
=====================

CD133/STAT3/c-MYC gene profiling in subgroups of MB
---------------------------------------------------

MB microarray data for 103 MBs were downloaded from GEO (GSE21140). These data consisted of processed Affymetrix CEL files (Affymetrix Human Exon 1.0 ST Array (transcript (gene) version)) that had undergone gene-level analysis (CORE content), quantile normalization (sketch) and summarization using PLIER with PM-GCBG background correction for 103 MBs. Clinical annotations for each MB tumor, including subgroup (Wnt, Shh, Group 3, Group 4) were also downloaded from this location. The expression of each gene was plotted as the normalized fluorescence intensity of the corresponding affymetrix probes. Similarly, raw Affymetrix datasets for 62 primary human MBs, 40 primary human MBs, 15 Daoy MB cell line samples and 46 primary human MBs were respectively downloaded and processed from GEO (GSE10327, GSE12992 and GSE7578) or <http://www.stjuderesearch.org/site/data/medulloblastoma>^[@bib28]^ and normalized using RMA.^[@bib53]^ When available, clinical annotations for each tumor were also downloaded from these locations.

CD133 signature for survival using Pomeroy database
---------------------------------------------------

Survival analysis (for CD133) was completed in (R core team, Vienna, Austria), and Kaplan--Meier survival curves were drawn using GraphPad prism (GraphPad software, SanDiego, CA, USA).

MB cell culture
---------------

MB cell lines Med8A, D425 and D458 were cultured in DMEM high glucose (Life Technologies, Carlsbad, CA, USA; \#11965-118) supplemented with 1% penicillin--streptomycin, 1% glutamine (Gibco) and 20% serum for Med8A, D425 and D548. CHLA-01R-MED (ATCC, Manassas, VA, USA; CRL-3034) was obtained the American Type Culture Collection (ATCC) and maintained in tumor sphere media as described previously.^[@bib54]^

Virus preparation and transduction
----------------------------------

Lentiviral vectors shSTAT3-1 and shSTAT3-2 expressing short-hairpin RNA-targeting human STAT3 (target sequence: 5′-TGCATGTCTCCTTGACTCT-3′, 5′-TACCTAAGGCCATGAACTT-3′, respectively) and control scrambled short-hairpin RNA vector were purchased from Thermo Scientific (Waltham, MA, USA). CD133 overexpression vector was purchased from Genecopoeia (Rockville, MD, USA). Replication-incompetent lentivirus was produced. Briefly, after co-transfection of expression vector and packaging plasmids, viral supernatants were harvested 48 h after transfection. Thereafter, supernatant was filtered through a 0.45 μm cellulose acetate filter and precipitated with PEGit (System biosciences, Palo Alto, CA, USA). After precipitation, viral pellets were re-suspended in 1.0 ml of DMEM F-12 media and stored at −80 °C until further used. To generate stable shSTAT3 lines, MB cells were transduced with lentivirus prepared as stated above. After 48 h of transduction, cells were grown in media containing 1 μg/ml of puromycin to generate stable cell lines.

Western immunoblotting
----------------------

Proteins from cell lysates were extracted and quantified as described previously.^[@bib24]^ Briefly, 20 μg of total protein was run using 10% sodium dodecyl sulphate--polyacrylamide gel electrophoresis and proteins were then transferred to polyvinylidene fluoride membrane. Blots were probed for the following antibodies: anti-CD133 (1:500; Millipore, Etobicoke, ON, Canada; \#MAB4399 clone 17A6.1), anti-c-MYC (1:1000; Cell signaling, Danvers, MA, USA; \#5605), anti-STAT3 (1:1000; Cell Signaling \#9139), anti-phospho STAT3 (1:1000; Cell Signaling; \#4113), anti-GAPDH (1:40,000; Abcam, Toronto, ON, Canada; \#ab8245). Secondary antibodies were conjugated with horseradish peroxidase and procured from Bio-Rad (Mississauga, ON, Canada; Goat anti-mouse IgG) or Sigma (Oakville, ON, Canada; goat anti-rabbit IgG) and chemidoc was used for visualization of protein bands.

Cell proliferation assay
------------------------

Using 96-well plates, single cells were plated at a density of 1000 cells/200μl per well in quadruplicate for each sample and incubated for 4 days. After 4 days, 20μl of Presto Blue (Life technologies), a cell viability indicator, were added to each well \~4 h prior to the readout time point. Fluorescence was measured using a FLUOstar Omega Fluorescence 556 Microplate reader (BMG LABTECH) at excitation and emission wavelengths of 540--570 nm and 580--610 nm, respectively. Readings were analyzed using MARS data analysis software (Guelph, ON, Canada).

Cell sorting and analysis using flow cytometry
----------------------------------------------

Tumorspheres/cell aggregates were dissociated using liberase (Roche, Laval, QC, Canada) and cells at a concentration of 1 million single cells/ml in phosphate-buffered saline+2 m[M]{.smallcaps} EDTA were stained with APC-conjugated anti-CD133 or a matched isotype control (Miltenyi, Auburn, CA, USA). The MoFlo XDP Cell Sorter was used to analyze/sort samples and Kaluza software (Beckman Coulter, Mississauga, ON, Canada) was used for analysis. Mouse IgG CompBeads (BD, San Jose, CA, USA) were used for compensation and viability dye 7-AAD dye (1:10; Beckman Coulter) was added in samples to exclude dead cells. Purity check for CD133 expression levels after sorting was also performed.

Quantitative real-time--polymerase chain
----------------------------------------

Norgen Total RNA isolation kit was used for RNA extraction. RNA was quantified using NanoDrop Spectrophotometer ND-1000 (Thermoscientific, Wilmington, DE, USA). Using 1 μg RNA, complementary DNA was synthesized using qScript cDNA Super Mix (Quanta Biosciences, Beverly, MA, USA) and a C1000 Thermo Cycler (Bio-Rad, Mississauga, ON, Canada) with the following cycle parameters: 4 min at 25 °C, 30 min at 42 °C, 5 min at 85 °C, hold at 4 °C. qRT-PCR was performed using Perfecta SybrGreen (Quanta Biosciences) and an 4CFX96 instrument (Bio-Rad) as described previously.^[@bib55]^ Gene expression was quantified by using CFX Manager 3.0 (Bio Rad) software and expression levels were normalized to GAPDH/Actin expression. Primers are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Screening of MBSCs with STAT3 inhibitors
----------------------------------------

Dr Patrick Gunning provided a library of proprietary direct-binding STAT3 inhibitors. Cell proliferation in MBSCs (grown in DMEM supplemented with 20% fetal bovine serum) was determined by plotting percentage cell viability versus log dilutions of the inhibitors, giving IC~50~. To assess tumor inhibition in mice, compound PG-S3-002 was chosen for *ex vivo* treatment and modification of compound PG-S3-002 resulted in synthesis of compound PG-S3-009, which has increased bioavailability and was used for *in vivo* treatment. See [Supplementary Figure 8](#sup1){ref-type="supplementary-material"} for details about PG-S3-009.

*In vivo* intracranial injections of MB stem cells and H&E staining of xenograft tumors
---------------------------------------------------------------------------------------

The McMaster University Animal Research Ethics Board (AREB) approved all experimental procedures and intracranial injections were performed as described previously.^[@bib13]^ Briefly, live cells (numbers mentioned in figure legends) re-suspended in 10 μl of phosphate-buffered saline were injected into the frontal lobe of NOD-SCID mice (both males and females of 8-10 weeks of age). Mice injected with CD133 sorted cells (positive or negative) were killed when the CD133-positive group reached end point. Treated mice (with either shSTAT3 or *ex vivo* STAT3 inhibitor or *in vivo* STAT3 inhibitor) were killed when control Group/untreated mice reached end point as shown by signs of illness, for tumor size quantification. Mice were randomized into control or treatment groups. Group allocation was not blinded. For survival studies, treated or control mice were killed when they reached end point. The treatment did not induce adverse weight loss that would be contraindicated by our animal utilization protocol (AUP) endpoints policy.

Mouse brains were harvested, formalin-fixed and thereafter brain sections were paraffin-embedded and also stained for hematoxylin and eosin (Cell Signaling). Aperio Slide Scanner (Leica Biosystems, Concord, ON, Canada) was used to scan images and images were analyzed using ImageScope v11.1.2.760 software (Aperio, Concord, ON, Canada). Survival curves were plotted using Graphpad Prism 5 (SanDiego, CA, USA).

Statistical analysis
--------------------

Technical/experimental replicates from at least three samples were compiled for each experiment, unless otherwise stated in figure legends. Respective data represent mean±s.d. with *n* values listed in figure legends. Student's *t-test* analyses and two-way analysis of variance were performed using GraphPad Prism 5. *P*\<0.05 was considered significant. For *in silico* analyses, statistical tests were complied and completed in R.
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![CD133 characterizes group 3 MB and CD133^+^ cells show increased tumorigenicty and proliferation as compared with CD133^−^ populations: MB cell lines are grown in their respective media conditions as described in the 'Materials and methods' section. (**a**) Representative flow cytometry plots exhibiting percentage of CD133 protein levels in Med8A (4.75%), D425 (39.13%), D458 (68.62%) and CHLA-01R-MED (98.27%). (**b**) Phase-contrast pictures of the above cell lines showing difference in their morphology and growth patterns. (**c**) CD133 expression identifies Group 3 MB (indicated as Group C) that was probed using affymetrix exon array data and expression levels represented by log2--transformed intensity signal. Four independent databases were probed to measure CD133 expression levels. (**d**) The CD133 signature was originally identified and described by Venupogal *et al.*(55) and CD133 signature genes are included as [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. CD133-high signature reflects a reduced overall survival of MB patients compared with CD133-low tumors (hazard ratio=2.4, *P*=0.01). (**e** and **f**) Group 3 MB cells D425 and D458 were flow cytometrically sorted into CD133^+^ and CD133^−^ populations and Presto Blue Assay assessed their proliferative potential. CD133^+^ cells are more proliferative when compared with CD133^−^ cells. Bar represents mean fluorescence intensity (arbitrary units (a.u.)) of three technical replicates, mean±s.d., two-tailed *t*-test, *P*⩽0.0007 (**g**) 500 000 cells of each of CD133^+^ and CD133^−^ populations were xenografted intracranially in mice brains. CD133^+^ cells generated larger and infiltrative tumors than CD133^−^ cells (scale bar=4 mm).](onc2016235f1){#fig1}

![STAT3 marks non-Shh/Wnt MB and its expression parallels CD133 expression. (**a**) affymetrix exon data from four independent databases shows STAT3 expression enriched in non-Shh/Wnt MB, that is, enrichment in Group 3 and Group 4 tumors (indicated as Group C and Group D respectively). Expression units are in log2 scale. (**b**) Immunoblot analysis for CD133, STAT3, activated STAT3 (p-STAT3) was performed in Group 3 and Group 2 MB lines. GAPDH was used as a loading control. To verify correlation between CD133 and STAT3, CD133 is overexpressed in Med8A. CD133 (**c**) transcript by qRT-PCR and (**d**) protein levels as shown by flow cytometric analysis (percentage increase from 5.03% to 82.18%, representative flow) are significantly increased following overexpression of CD133 (oe CD133). (**e**) Med8A oe CD133 showed increased p-STAT3, although no change in STAT3 was seen. (**f**) Proliferative capacity measured using Presto Blue assay shows OE CD133 cells have a significant increase in proliferation when compared with OE con (control cells). Bar represents mean fluorescence intensity (arbitrary units (a.u.)) of three technical replicates, mean±s.d., two-tailed *t*-test. \**P*\<0.05.](onc2016235f2){#fig2}

![STAT3 knockdown using lentiviral approach reveals its role in proliferation and tumor formation. shSTAT3 lentiviral vector-mediated transduction shows reduction in both STAT3 and phosphorylated p-STAT3 protein levels as assessed by immunoblotting with shSTAT3-1 vector compared with shControl vector in both (**a**) D425 and (**b**) D458 cell lines. GAPDH was used as a loading control. Proliferative capacity as determined by Presto Blue assay shows decreased proliferation in shSTAT3-1 (**c** and **d**) when compared with shControl-transduced cells. Bar represents mean fluorescence intensity (arbitrary units (a.u.)) of three technical replicates, mean±s.d., two-tailed *t*-test. \**P*⩽0.01. (**e**) Xenografts were generated using 100 000 cells of shControl or shSTAT3-1 vectors in D425 (upper panel) and D458 (lower panel) into the frontal lobes of NOD-SCID mice (*n*=6 in each group). shSTAT3-1-treated cells displayed significantly small and less invasive tumors in both lines (arrows indicates tumor area). Mice were killed in pairs of shControl and shSTAT3-1 when one member of the pair reached end point and H&E sections of the brains are shown. (**f** and **g**) Total area of tumor was calculated using ImageJ64 software (NIH, Bethesda, MA, USA). Bar represents tumor area (mm^2^) of *n*=6 mice in each group, mean±s.d. and two-tailed *t*-test. \**P*⩽0.005. (**h** and **i**) shSTAT3 cells xenograted mice maintain a significant survival over shControl-treated mice (*n*=3 in each group). The median survival in case of D425 shSTAT3 mice increased to 38 days compared with 20 days in shControl mice (*P*=0.0072) and median survival in D458 shSTAT3 mice augmented to 33 days from 24 days in shControl mice (*P*=0.04).](onc2016235f3){#fig3}

![CD133, STAT3 and c-MYC constitute a signaling axis in MBSC regulation. (**a**) transcript by qRT-PCR and (**b**) protein levels as shown by western blotting. Bar represents expression levels relative to GAPDH of three technical replicates, mean±s.d., one-way analysis of variance, *P*⩽0.004. D458 cells were flow cytometry sorted for CD133^+^ and CD133^−^ populations. c-MYC (**c**) transcript by qRT-PCR and (**d**) protein levels in D458 as shown by western blotting are significantly increased in CD133-positive cells when compared with CD133-negative cells. CD133^+^ cells also showed increased protein expression of CD133 and p-STAT3 relative to GAPDH control as analyzed by western blotting. Bar represent expression levels relative to GAPDH of three technical replicates, mean±s.d., two-way analysis of variance, *P*=0.005. (**e**) D425 and D458 cells were treated with c-MYC inhibitor 10058-F4 and IC~50~ curves were generated from inhibition of cell proliferation using Presto Blue assay with four technical replicates. IC~50~ values are: D425: 189.148 μ[M]{.smallcaps} and D458: 133.277 μ[M]{.smallcaps}.](onc2016235f4){#fig4}

![STAT3 inhibitors targeting MBSCs. (**a**) D425 and (**b**) D458 cells were flow cytometry sorted into CD133^+/−^ populations and treated with PG-S3-002 STAT3 inhibitor. IC~50~ curves were generated from inhibition of cell proliferation using presto blue assay with four technical replicates. For D425, IC~50~ values are; CD133^+^: 2917 n[M]{.smallcaps} and CD133^−^: 13 794 n[M]{.smallcaps}. IC~50~ values for D458 are CD133^+^: 7807 n[M]{.smallcaps} and CD133^−^: 11 424 n[M]{.smallcaps}. (**c** and **d**) Western blot showing protein levels of STAT3 and phosphorylated STAT3 (p-STAT3) in DMSO-treated and PG-S3-002-treated (IC~80~) D425 and D458, relative to GAPDH control. (**e**) D425 (upper panel) and D458 (lower panel) cells were treated *ex vivo* with their respective IC~80~ of PG-S3-002 for 4 days and 100 000 viable cells were injected into frontal lobes of NOD-SCID mice (*n*=3 in each group). Cells treated with DMSO were used as control. Mice were killed in pairs as they fell sick. H&E sections of the brains are shown. Average tumor size reduction is 85% in (**f**) D425 and 70% in (**g**) D458. Tumor area was calculated using ImageJ64 software (NIH). Bar represents tumor area (mm^2^) of *n*=3 mice in each group, mean±s.d. and two-tailed *t*-test. \**P*⩽0.005.](onc2016235f5){#fig5}

![*In vivo* treatment with STAT3 inhibitors in recurrent MB cells. (**a**) unsorted D458 cells were treated with STAT3 inhibitors PG-S3-009 and PG-S3-010 and IC~50~ curves generated from inhibition of cell proliferation using Presto Blue assay with four technical replicates. For middle and right panels, D458 cell are sorted by flow cytometry into CD133^+^ and CD133^−^ populations and then IC~50~ curves were generated. Left panel: IC~50~ values for PG-S3-009 and PG-S3-010 are 3943 n[M]{.smallcaps} and 2747 n[M]{.smallcaps} for total population, respectively. Middle panel: after treatment with PG-S3-009, sorted cells have IC~50~ values 3254 n[M]{.smallcaps} and 44 232 n[M]{.smallcaps} for CD133^+^ and CD133^−^ population, respectively. Right panel: after PG-S3-010 treatment, IC~50~ values were 2517 n[M]{.smallcaps} and 39 511 n[M]{.smallcaps} for CD133^+^ and CD133^−^ and populations, respectively. (**b**) Timeline of the *in vivo* treatment protocol. Day 0 is the first day of tumor implantation in mice (*n*=15 mice). D458 recurrent MB cells are used. After a week of implantation, treatment protocol of 20 mg/kg body weight of DMSO, PG-S3-009 or PG-S3-010 (*n*=5 mice in each set) started with intraperitoneal injections twice a week for 2 weeks. At the end of 2 weeks, mice were killed and their brains were harvested. (**c**) Representative H&E sections of the brains are shown (*n*=5). (**d**) Tumor area was calculated using ImageJ64 software (NIH). Bar represents tumor area (mm^2^) of *n*=5 mice in each group, mean±s.d. and two-tailed *t*-test. \**P*⩽0.005. Average tumor size reduction is 80% in treatment with PG-S3-009 and 35% in PG-S3-010.](onc2016235f6){#fig6}

![Dose-dependence study of PG-S3-009. (**a**) Western blot showing c-MYC, STAT3 and p-STAT3 levels compared to GAPDH after treatment of D458 with serially increasing concentration of PG-S3-009. (**b**) Timeline of the *in vivo* protocol starting with 48 mice intracranial injections (frontal lobe) of D458 at day 0, day of tumor cell implantation. After a week, (*n*=12 mice in each set) were given 5, 10 or 20 mg/kg body weight of either DMSO or PG-S3-009 for 2 weeks, twice a week. At the end of third week, mice were killed (*n*=6 mice in each set) for H&E staining and remaining 6 mice per set were monitored for their survival. (**c**) Representative H&E sections of the brains are shown after each treatment regimens (*n*=6). (**d**) There is a significant reduction in tumor area (calculated using ImageJ software). Bar represents tumor area (mm^2^) of *n*=6 mice in each group, mean±s.d. and two-tailed *t*-test. \**P*=0.03. (**e**) Percentage survival for mice treated with 5 mg (upper panel), 10 mg (middle panel) and 20 mg/kg body weight of PG-S3-009 (lower panel).](onc2016235f7){#fig7}
